XVIVO Heart Assist Transport (XHAT) With Supplemented XVIVO Heart Solutuion (SXHS) Continued Access Protocol (CAP) (NIHP-CAP-001)

XVIVO

Status

Begins enrollment this month

Conditions

Transplant; Failure, Heart

Heart Failure

Heart Transplant

Treatments

Device: Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)

Study type

Interventional

Funder types

Industry

Identifiers

NCT06895070

NIHP-CAP-001

Details and patient eligibility

About

The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.

Full description

This is a continuation of the PRESERVE IDE trial to provide additional data evaluating the safety and effectiveness of the XVIVO Heart Assist Transport System. The PRESERVE Continued Access Protocol (CAP) will utilize the XHAT System to preserve donor hearts that may not meet current standard donor heart acceptance criteria with the intention of these hearts being transplanted. The CAP has been implemented to allow patients and physicians access to the XHAT System while a Post-Market Approval (PMA) application is being submitted and reviewed.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria Recipient:

To be eligible to participate in this study, a recipient must meet all the following criteria:

Age ³18 years.
Signed informed consent form (ICF).
Listed for heart transplantation.

Exclusion Criteria Recipient:

Previous solid organ or bone marrow transplantation.
Requires a multi-organ transplant.
Subject is enrolled and ongoing in another investigational pharmaceutical or medical device clinical trial (Exception: observational studies are permitted).
Subject is on mechanical circulatory support pre-transplant other than durable LVAD, Impella or intra-aortic balloon pump (IABP).
History of complex congenital heart disease ie: single ventricle physiology (per Investigator's discretion and XVIVO review).
Subject on renal replacement therapy/dialysis.
Ventilator dependence (subject is intubated at time of transplant/unable to provide consent or re-affirmation of consent).
Sensitized participants meeting any of the following:
- Participant with calculated Panel Reactive Antibody (cPRA) greater than 50%
- Participant undergoing any desensitization treatment (also with cPRA less than 50%)
- Participant with a positive prospective crossmatch and/or a positive virtual cross match

Donor Inclusion Criteria:

To be eligible to participate in this study, the donor heart must meet the following criteria:

Estimated Cross Clamp Time ≥4 hours OR
Estimated Cross Clamp ≥ 2 hours AND

Any one or more of the following:

Age ≥50 years
LVEF 40% - 50% at time of provisional acceptance. (Refer to section 6.3.4 for definition of provisional acceptance).
Down-time ≥20 minutes
Hypertrophy septal thickness >12 - ≤16mm
Angiographic luminal irregularities with no significant CAD OR 1) Donation after Circulatory Death (DCD)

Donor Exclusion Criteria:

Donor hearts that meet any of the following criteria will be excluded from transplantation in this study:

Unstable hemodynamics requiring high-dose inotropic support.
Significantly abnormal coronary angiogram defined as CAD > 50% stenosis of one or more vessels or if the donor heart exhibits any contusions, structural damage, gross abnormalities, or palpable CAD on final examination.
Moderate to severe cardiac valve pathology.
Investigator's clinical decision to exclude from trial.
Previous sternotomy.